Hartwig Klinker

机构：University of Würzburg, Universitätsklinikum Würzburg · ORCID：0000-0001-7140-6786

发表论文 323 篇 · 总被引 5134 次 · h-index 39

代表论文

• DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function (2022 · Infection · 被引 86)
• Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure (2022 · Journal of Hepatology · 被引 26)
• A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients (2022 · Pharmaceutics · 被引 16)
• Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib (2023 · Journal of Pharmaceutical and Biomedical Analysis · 被引 15)
• Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma (2022 · Cancers · 被引 11)
• Therapeutic Drug Monitoring of Long-Acting Rilpivirine and Cabotegravir for Treatment of HIV-1 Infection—A Case Series of Five Patients With One Virologic Failure After Development of Two-Class Resistance (2024 · Open Forum Infectious Diseases · 被引 8)